- Home
- OIA vs VNDA Comparison
OIA vs VNDA Comparison
Compare OIA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIA | VNDA |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.4M | 361.4M |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | OIA | VNDA |
|---|---|---|
| Price | $5.67 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 105.6K | ★ 626.6K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $5.60 | $4.27 |
| 52 Week High | $6.40 | $9.91 |
Technical Indicators
Market Signals| Indicator | OIA | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 36.86 | 45.89 |
| Support Level | N/A | $4.94 |
| Resistance Level | $6.24 | $5.62 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 34.09 | 27.14 |
Price Performance
Historical ComparisonAbout OIA Invesco Municipal Income Opportunities Trust
Invesco Municipal Income Opportunities Trust is a closed-end management investment company. The Trust's investment objective is to provide a high level of current income which is exempt from federal income tax.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.